agents, such as plasma-derived activated prothrombin complex concentrates (aPCC) or activated recombinant factor VII (rFVIIa). [2] [3] [4] [5] Primarily out of concern for thrombosis, most clinicians use a titrated, "lowest effective" dose of bypassing agent in acute bleeding episodes. 6, 7 In an early review of rFVIIa dosing, Abshire and Kenet 8 proposed that optimization of the initial thrombin burst in patients at low thrombotic risk may lead to earlier and possibly more durable haemostasis. Optimal dose finding is further complicated by the absence of validated pharmacodynamic markers to predict clinical efficacy.
Retrospective rFVIIa utilization data in the congenital haemophilia inhibitor population indicate the risk of thrombin generation at sites where pathologic thrombosis is triggered, rather than physiologic haemostasis, is related to the presence of pre-existing risk factors for thrombosis. 9, 10 To date, clinical evidence suggestive of dosedependent efficacy has been generated, but this has been difficult to confirm or reproduce for reasons that are not well understood. [11] [12] [13] [14] [15] Historically, various dosing regimens have been employed attempting improvements in overall rFVIIa haemostatic efficacy and dosing efficiency. In on-demand settings, there is weak evidence that the AUC of a bypassing agent is the primary correlate for the achievement of haemostasis, though the effect of sustained thrombin generation is thought to improve healing and may delay clot dissolution. 16, 17 Not surprisingly, continuous infusion in the setting of surgical interventions (with ongoing wound manipulation) has been shown to be efficacious, thus confirming that a steady concentration of agent may have benefit in certain clinical circumstances. In contrast, animal experiments and some prospective human studies make clear that the peak plasma concentration (C max ) of administered FVIIa is correlated with thrombin generation, clot strength and faster onset of haemostasis. [18] [19] [20] [21] [22] Whether incremental dosing could delay otherwise achievable early haemostasis is unclear. The primary sequence and the degree of gamma carboxylation of eptacog beta and eptacog alfa are identical. The ex vivo molar potency of eptacog beta is greater, and differences in glycosylation and binding to cellular sites such as Endothelial Protein C Receptor and platelets have been observed.
| MATERIALS AND METHODS
This study received approval by institutional review boards, and was conducted in compliance with established good clinical practice as stated in the current Declaration of Helsinki. 25 Written informed consent was obtained from all subjects at the time of their enrollment.
The study is registered at clinicaltrials.gov (NCT01708564).
| Study design
Three doses of rhFVIIa (25, 75 and 225 μg/kg) were examined using a Phase Ib dose-escalation study design. Doses were preselected based on preclinical in vitro and in vivo studies of activity [LFB SA Data on File]. The first 10 subjects received the lowest dose of rhFVIIa.
Following review of the 30 ± 6 hour safety and PD coagulation data by an independent, external Data Monitoring Committee (DMC), 5 of these subjects were randomly selected and 5 new subjects received the second treatment dose. Following a similar safety review by the DMC, the 5 remaining subjects treated at dose level 1, and the 5 newly treated subjects from dose level 2 were treated with the highest dose.
Open label study drug was administered intravenously over 2-3 minutes; a single lot of drug product was used throughout the study. Two centres in the US and 1 in The Netherlands enrolled subjects Figure 1 .
| Patients
Male subjects, aged 18-75 years, with moderate or severe congenital haemophilia A or B (FVIII or FIX levels <5% of normal) were eligible to enrol. Subjects with prothrombotic risk factors were excluded from the study. Key inclusion and exclusion criteria are listed in Table 1 .
| Pharmacokinetic, pharmacodynamic and safety evaluations
PK, PD and safety assessments were obtained not more than 30 minutes prior to dosing (baseline); at 5, 15 and 30 minutes; and at 1, 2, F I G U R E 1 To insure that each subject received 2 different doses of rhFVIIa, the trial followed a predetermined, systematic dose-escalation scheme starting with the low dose and increasing in subsequent cohorts 
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| Pharmacokinetics
The StaClot ® FVIIa rTF assay (Diagnostica Stago™), modified and validated to accommodate high FVIIa concentrations, was used to measure functional plasma rhFVIIa concentrations against a validated in vitro standard. Sampling was planned to evaluate peak thrombin generation at intervals, allowing dose proportional statistical modelling of plasma rhFVIIa activity over time. This assay does not distinguish exogenous rhFVIIa from endogenous FVIIa; however, as administered doses of rhFVIIa produce plasma levels that greatly exceed levels of endogenous FVIIa, 26 the assay is a valid measure of clinically relevant rhFVIIa plasma levels. 
| Pharmacodynamics
| Immunogenicity
Blood samples were analyzed for antibodies against rhFVIIa (all antibody isotypes) and potential production-related impurities immediately prior to rhFVIIa administration; at the 30 ± 6 hour safety evaluation, and at the 14 ± 1 day and 28 ± 2 day follow-up visits. Per the immunogenicity testing protocol, neutralizing antibodies in the sensitive screening immunochemical assay required the confirmation of antibody specificity by inhibition by study drug. All samples were confirmed negative for antidrug antibody. Thus, no functional inhibitory assays were required.
| Safety
Safety assessments included full medical history, concomitant medication use, and a standard physical examination at screening and at the 28-day follow-up visit. Electrocardiograms were conducted at screening, baseline, and 30 ± 6 hours after drug administration. Clinical laboratory tests included haematology, urinalysis, coagulation-based antibody screening, antibody assays and serum chemistry at screening, baseline, 30 ± 6 hours, and 14 days after drug administration (FVIII or FIX inhibitors, HBsAg, HCV, HIV).
| Statistical methods
Descriptive statistics for plasma concentrations of rhFVIIa activity at each protocol designated time point were tabulated and individual PK parameters were determined using a non-compartmental PK analysis.
For each PD variable, descriptive statistics were analyzed by time point and dose group for actual values and change from baseline. Baselinecorrected levels were reported as indicated. The 24-hour safety evaluation time point was not used in the PK analysis. Due to the study design, significance testing was not performed.
| RESULTS
| Subject population
Eighteen subjects were screened: 15 of these satisfied the inclusion and exclusion criteria and received both assigned doses of rhFVIIa. 14 of these subjects completed all follow-up evaluations, with 1 subject being lost to both the 14 and 28-day safety assessments following the second dose. Demographics are shown in Table 2 . 
| Pharmacokinetics
| Pharmacodynamics
The effects of binding of rhFVIIa to platelets is more prominent than those of tissue factor binding. Thus, a platelet-spiked TGA assay (TGAp) is more representative of its clinical mode of action than the platelet-free assay. 18, 27, 28 Plasma samples were obtained at prespecified times after rhFVIIa administration. Thrombin generation was measured and mean thrombin generation peaks were calculated.
Dose-dependent effects were seen in the peak thrombin generation when measured from 5 minutes to 24 hours ( Figure 3 and Table 4 ).
The platelet-free TGA showed significant variability, and the results are not reported here.
Baseline aPTT uniformly exceeded the upper limit of the normal range (23 to 34 seconds) ( Table 4 Reduction in prothrombin time was observed at all doses, but greatest in the 75 and 225 μg/kg dose groups (Table 4) . At baseline, the mean PTs were comparable for all groups and were within the normal range (13.1-15.7 seconds). Full evidence of dose dependency was obscured, as the lower limit of the assay (approximately 8 seconds)
was reached with both the 75 and 225 μg/kg doses. The PT returned to baseline by 12 hours following the 25 μg/kg dose, and by 24 hours following the higher doses.
| ROTEM (modified)
Clot firmness is a measure of the absolute strength of the fibrin and platelet clot and in this study, the change from baseline also exhibited a dose-dependent relationship (Figure 4 ). Maximum clot firmness (MCF) was observed 5 minutes postinfusion, with the change from baseline being 5.9 ± 3.7, 7.0 ± 2.8, and 9.7 ± 3.3 mm for the 25, 75, and 225 μg/kg dose groups, respectively. (Table 4) 
| Measures of coagulation activation
Baseline D-dimer levels were variable among subjects; however, individual subject levels remained largely unchanged throughout the evaluation period, as did the mean levels. One subject had elevated levels at the 24 hours time point on the 225 μg/kg dose, being 2-fold higher than baseline, and occurring 24 hours postinfusion.
Prothrombin fragment F1+2 showed a dose-dependent increase with a peak 1 to 2 hours postinfusion, indicating the formation of thrombin following rhFVIIa administration. Levels returned to baseline between 6 and 12 hours postinfusion. When the change from baseline value was calculated, a low level dose-response was observed: the median change from baseline at 2 hours was 33, 94 and 164 pmol/L for the 25, 75, and 225 μg/kg groups, respectively.
TAT, a complex between thrombin and antithrombin, is a marker of coagulation activation, and is highly variable among normal individuals.
Overall, the 25 μg/kg dose appeared to have no effect on thrombinantithrombin complex behaviour. TAT levels for the 75 and 225 μg/ kg dose groups were variable and inconsistent between patients, with 
| Immunogenicity
No hypersensitivity or humoral immunogenicity was detected in any subject during primary or re-exposure assessments.
| Safety
In all 3 cohorts, both doses of rhFVIIa (25/75, 25/225 or 75/225 μg/ kg) were well tolerated. Three adverse events that occurred within 36 hours of infusion were possibly related to the drug based upon the temporal relationship between the events and drug infusion. One patient experienced mild dizziness of short duration after receiving doses of 25 and 75 μg/kg rhFVIIa (11 and 3 minutes' duration respectively).
A second patient experienced a mild headache that lasted for 2 hours following administration of 25 μg/kg rhFVIIa. All events resolved without intervention. There were no clinically meaningful excursions in hematologic or serum chemistry measures following administration.
There was no evidence of administration-related allergic reaction. and FVIIa is known to enhance FVIIa-driven haemostasis in vivo. 29 In in vitro studies, Grandoni et al 5 demonstrated that rhFVIIa binds to EPCR 25%-30% more effectively than the predecessor rFVIIa product, eptacog alfa. In addition, it has been suggested that a second minor binding site may exist for rhFVIIa, but not eptacog alfa. 25 µg/kg rhFVIIa 75 µg/kg rhFVIIa 225 µg/kg rhFVIIa exposure to the product. This clinical tolerability was corroborated by negative immunologic assays.
| CONCLUSION
Data from this dose escalation study provide guidance for clinical dose selection for future rhFVIIa studies. The peak plasma concentration of rhFVIIa has relevant effects on platelet augmented thrombin generation, suggesting dose-dependent increases in local thrombin concentration at the site of bleeding. Further, time to clot formation and clot structure, strength and retractive force development are directly related to the peak thrombin generation within the forming clot. 18, [33] [34] [35] Thus, C max considerations should guide the choice of the initial dose for on-demand treatment of bleeding episodes. In addition, the total AUC determined at different doses confirms the viability of a 3-hour dosing interval for the 75 μg/kg and suggests that a 9-hour dose-dependent interval between the initial 225 μg/kg and subsequent doses are pharmacokinetically supported. This key consideration permits design of an on-demand dosing regimen. Without clinically validated PD markers to predict bypassing agent efficacy in bleeding haemophilia subjects with inhibitors, a subsequent Phase 3 study was initiated (using 75 and 225 μg/kg as initial doses) to validate these results. 23, 24 Activated eptacog beta (rhFVIIa), a new second-generation rhFVIIa, was well tolerated in haemophilia patients with or without inhibitors, and had dose-dependent PK and PD profiles that support further evaluation of its potential efficacy in studies of bleeding episodes in haemophilia patients with inhibitors.
